Tekla Capital Management’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Tekla Capital Management’s Portfolio THRX Stock Details THRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$700K	Hold	75,000	–	–	0.03%	134
2023 Q1	$666K	Sell	75,000 -25,000	-25%	-$245K	0.03%	141
2022 Q4	$498K	Hold	100,000	–	–	0.02%	148
2022 Q3	$580K	Hold	100,000	–	–	0.02%	144
2022 Q2	$553K	Hold	100,000	–	–	0.02%	148
2022 Q1	$1.15M	Hold	100,000	–	–	0.04%	141
2021 Q4	$1.27M	Buy	+100,000	New	+$1.51M	0.04%	142

Other funds holding THRX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Tekla Capital Management's THRX Position: Q2 2023 in Review

Tekla Capital Management held its Theseus Pharmaceuticals, Inc. Common Stock (THRX) position steady in Q2 2023 at 75,000 shares worth $700K. The position accounts for 0.03% of the portfolio, ranked #134.

Tekla Capital Management first reported a position in THRX in Q4 2021 and has held it in 7 quarters since. The position peaked at $1.27M in Q4 2021. 69 funds tracked by Wall St. Rank hold THRX as of Q2 2023.

Tekla Capital Management held 75,000 shares of Theseus Pharmaceuticals, Inc. Common Stock worth $700K as of Q2 2023.
Tekla Capital Management left its Theseus Pharmaceuticals, Inc. Common Stock share count unchanged in Q2 2023.
Theseus Pharmaceuticals, Inc. Common Stock made up 0.03% of Tekla Capital Management's portfolio in Q2 2023, its #134 holding.
Tekla Capital Management first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q4 2021 and has held it in 7 quarters since.
Tekla Capital Management's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $1.27M in Q4 2021.
69 funds tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.